Abstract 2749
Background
With the expanding use of CPI in different types of cancer, we have been challenged with the lack of safety and efficacy data of CPI post allogeneic stem cell therapy (SCT).
Methods
We systematically reviewed our institutional databases through March 2018 and identified patients (pts) who received CPI for treatment of cancer after allogeneic SCT. In addition, we systematically reviewed the literature through August 2018 to identify studies reporting use of CPIs post-allogeneic SCT. We evaluated the prevalence of graft vs host disease (GVHD), immune-related adverse events (irAEs), tumor response, and mortality after CPI.
Results
A total of 38 pts were identified (10 from institutional databases & 28 from literature). The median age was 37.5 years (range 10–68 yrs). The most commonly used CPI was anti-PD1 84 %. Cancer types included hematologic malignancies (n = 36); primarily Hodgkin lymphoma in 58%, and solid tumors (n = 2). Median time to CPI initiation post SCT was 1.6 years (range 0.92–32 yrs). More than half of pts (59 %) were maintained on immunosuppressive agents: brentuximab vedotin, cyclophosphamide, and low dose prednisone at CPI initiation. GVHD occurred in 34.2 % (n = 13); nine were specified having acute GVHD (82%). The median time from initiation of CPI to GVHD was 14 days (range 5-21 days). In most pts, GVH was treated with steroids. Two thirds of pts achieved complete or partial tumor remission (ORR 66%), while 28% had disease progression. In pts who developed GVHD the ORR was 91.2%. Interestingly, of the 25 pts who were reported to have no GVHD, 10 had irAEs. There were total of 34% of death (n = 13), including 5% only (n = 2) were attributed to GVHD, while the remaining were secondary to either progression of disease, CPI irAE’s (Pneumonitis, Myocarditis), and other causes.
Conclusions
The use of CPI post-SCT has a significant anti-tumor response, but it was associated with an increased risk of acute GVHD. Prospective studies in this population (CPI post-SCT) with longitudinal on treatment biopsies are needed to understand the differences between allo-immunity, tumor immunity and auto-immunity (irAE).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Adi Diab.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract